Moderna’s stock jumped more than 70% after the FDA cast a unanimous 9‑0 vote approving its latest vaccine. The move is a textbook example of how a single regulatory milestone can send a company’s shares soaring. For retail traders, the headline is a reminder that news‑driven spikes are often short‑lived, especially when analysts project a significant long‑term pullback.
Despite the rally, Wall Street’s consensus price target still expects a 44% drop from the current level. This divergence points to a broader concern that the company’s growth prospects may not justify the inflated valuation. In a market that is currently labeled “Extreme Fear,” with Bitcoin hovering around $62,000 and Ethereum near $1,738, investors are more cautious about chasing high‑growth stocks. The crypto environment’s volatility can spill over into equities, making it harder for a single positive event to sustain momentum.
For those watching the intersection of biotech and crypto, the next key events to monitor are the company’s upcoming earnings report and any further FDA announcements. If Moderna can demonstrate robust sales and a clear pipeline, the stock may defy the bearish target. Conversely, if the market perceives the approval as a one‑off win, the price could retrace, mirroring the broader risk‑off sentiment that is currently dominating both the equity and crypto markets.